clofarabine has been researched along with busulfan in 27 studies
| Studies (clofarabine) | Trials (clofarabine) | Recent Studies (post-2010) (clofarabine) | Studies (busulfan) | Trials (busulfan) | Recent Studies (post-2010) (busulfan) |
|---|---|---|---|---|---|
| 424 | 101 | 280 | 4,967 | 645 | 1,426 |
| Protein | Taxonomy | clofarabine (IC50) | busulfan (IC50) |
|---|---|---|---|
| Matrix metalloproteinase-9 | Homo sapiens (human) | 5.215 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 23 (85.19) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Andersson, BS; Valdez, BC | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Murray, D; Valdez, BC | 1 |
| Alousi, A; Andersson, BS; Champlin, RE; de Lima, M; Hosing, C; Jones, RB; Kebriaei, P; Madden, T; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Wang, X; Worth, LL | 1 |
| Abonour, R; Baute, J; Cox, E; Farag, SS; Jones, DR; Kane, K; Nelson, RP; Robertson, MJ; Schwartz, JE; Secrest, A; Srivastava, S; Sullivan, C; Wood, LL | 1 |
| Braun, T; Choi, S; Elenitoba-Johnson, K; Erba, H; Ferrara, J; Frame, D; Harris, A; Jones, D; Kitko, C; Kujawski, L; Levine, J; Magenau, J; Mineishi, S; Paczesny, S; Pawarode, A; Peres, E; Reddy, P; Sanks, J; Tobai, H; Yanik, G | 1 |
| Alousi, A; Andersson, BS; Basset, R; Champlin, RE; Ciurea, S; de Lima, M; Hosing, C; Jones, RB; Kebriaei, P; Khouri, I; Ledesma, C; Nieto, Y; Parmar, S; Popat, U; Qazilbash, M; Shpall, EJ | 1 |
| Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH | 1 |
| Andersson, BS; Champlin, RE; Corn, P; Dominguez, JR; Li, Y; Song, G; Valdez, BC | 1 |
| Bilger, K; Blaise, D; Chevallier, P; de La Tour, RP; Delaunay, J; El-Cheikh, J; Furst, S; Guillaume, T; Labopin, M; Lioure, B; Michallet, M; Milpied, N; Mohty, M; Moreau, P; Socié, G; Tabrizi, R; Vigouroux, S | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Song, G; Valdez, BC | 1 |
| Andersson, BS; Champlin, RE; Ji, J; Li, Y; Liu, Y; Murray, D; Popat, U; Valdez, BC | 1 |
| Alyea, E; Ballen, KK; Chen, YB; Cutler, C; Dey, BR; Driscoll, J; El-Jawahri, A; Ho, VT; Hunnewell, C; Li, S; McAfee, SL; Poliquin, C; Saylor, M; Soiffer, RJ; Spitzer, TR | 1 |
| Aoki, Y; Imai, K; Ishiwata, Y; Kajiwara, M; Miyawaki, R; Mizutani, S; Morio, T; Takagi, M; Tomizawa, D; Yasuhara, M | 1 |
| Andersson, BS; Brammer, JE; Champlin, RE; Hosing, C; Li, Y; Liu, Y; Murray, D; Nieto, Y; Teo, EC; Valdez, BC | 1 |
| Alatrash, G; Alousi, AM; Andersson, BS; Champlin, RE; Chen, J; de Lima, M; Fox, PS; Garber, HR; Hosing, C; Janbey, S; Jones, RB; Kebriaei, P; Ning, J; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Worth, LL | 1 |
| Becker, PS; Braun, T; Churay, T; Eapen, M; Forman, S; Frey, N; Hari, P; Jagasia, M; Khaled, S; Kim, DD; Lieland, S; Logan, B; Magenau, J; McGuirk, J; Mineishi, S; Parkin, B; Rowley, SD; Schechter, T; Scott, B; Wang, H; Westervelt, P | 1 |
| Aoki, Y; Fujimura, J; Hoshino, A; Imai, K; Ishiwata, Y; Kajiwara, M; Kanegane, H; Mae, T; Matsumoto, K; Mitsuiki, N; Miyamoto, S; Mizutani, S; Morio, T; Nishimura, A; Takagi, M; Takikawa, K; Tanaka, M; Tomita, O; Tomizawa, D; Yanagimachi, M; Yasuhara, M | 1 |
| Boelens, JJ; Egas, AC; Langenhorst, JB; Punt, AM; van Kesteren, C; van Maarseveen, EM | 1 |
| Claxton, D; Miki, K; Mineishi, S; Naik, S; Rakszawski, K; Shike, H; Wagner, H | 1 |
| Bierings, M; Boelens, JJ; Bresters, D; de Koning, CCH; Kollen, WJ; Lankester, AC; Lindemans, CA; Nierkens, S; Versluijs, AB | 1 |
| Ahmed, S; Alousi, A; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, S; Cool, R; Gulbis, A; Hosing, C; Kawedia, J; Kebriaei, P; Kornblau, S; Ma, J; Myers, A; Nieto, Y; Oran, B; Parmar, S; Popat, UR; Rezvani, K; Shah, N; Shpall, E; Thall, PF; Valdez, BC | 1 |
| Alatrash, G; Alousi, AM; Anderlini, P; Bassett, R; Champlin, RE; Chen, J; Daher, M; Hosing, C; Kawedia, J; Kebriaei, P; Ledesma, C; Lu, Y; Marin, D; Mehta, R; Nieto, Y; Olson, A; Oran, B; Popat, U; Qazilbash, M; Rondon, G; Saberian, C; Shpall, EJ; Thall, PF; Valdez, BC | 1 |
| Carulli, A; Catania, C; Connor, MP; Frey, NV; Freyer, CW; Gill, SI; Hexner, EO; Hollander, L; Loren, AW; Luger, SM; Mangan, JK; Martin, ME; McCurdy, SR; Perl, AE; Porter, DL; Pratz, KW; Smith, J; Stadtmauer, EA; Timlin, C; Zebrowski, AM | 1 |
3 review(s) available for clofarabine and busulfan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Busulfan; Clofarabine; Cross-Linking Reagents; Hematologic Neoplasms; Humans; Preoperative Care; Stem Cell Transplantation; Vidarabine | 2010 |
High-dose etoposide in allogeneic stem cell transplantation.
Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Busulfan; Carboplatin; Carmustine; Clinical Trials as Topic; Clofarabine; Cyclophosphamide; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Leukemia; Leukemia, Myeloid, Acute; Lomustine; Mucositis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy, Adjuvant; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2012 |
9 trial(s) available for clofarabine and busulfan
| Article | Year |
|---|---|
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Topics: Adenine Nucleotides; Animals; Antilymphocyte Serum; Antineoplastic Agents; Arabinonucleosides; Busulfan; Cell Line, Tumor; Clofarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Rabbits; Remission Induction; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Busulfan; Clofarabine; Combined Modality Therapy; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Factors; Stem Cell Transplantation; Survival Rate; Tissue Distribution; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Agents; Arabinonucleosides; Busulfan; Child, Preschool; Clofarabine; Disease-Free Survival; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Male; Middle Aged; Myeloablative Agonists; Remission Induction; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Homologous | 2011 |
Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Busulfan; Clofarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Transplantation Conditioning; Young Adult | 2012 |
Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.
Topics: Adenine Nucleotides; Adult; Aged; Antilymphocyte Serum; Arabinonucleosides; Busulfan; Clofarabine; Drug Administration Schedule; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous | 2014 |
Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.
Topics: Adenine Nucleotides; Adult; Aged; Arabinonucleosides; Busulfan; Chronic Disease; Clofarabine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning | 2016 |
A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.
Topics: Adenine Nucleotides; Adult; Aged; Allografts; Arabinonucleosides; Busulfan; Clofarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Transplantation Conditioning | 2017 |
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation.
Topics: Bayes Theorem; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Transplantation Conditioning; Vidarabine | 2022 |
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.
Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine; Vorinostat | 2022 |
15 other study(ies) available for clofarabine and busulfan
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Cycle Proteins; Cell Line, Tumor; Clofarabine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins; Vidarabine | 2011 |
The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
Topics: Adenine Nucleotides; Antineoplastic Agents, Alkylating; Apoptosis; Arabinonucleosides; Busulfan; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Clofarabine; DNA Damage; DNA-Binding Proteins; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia, Myeloid, Acute; Mitochondria; Nuclear Proteins; Signal Transduction; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2014 |
Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Clofarabine; DNA Damage; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Tandem Repeat Sequences; Vidarabine | 2014 |
Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Line, Tumor; Cladribine; Clofarabine; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Real-Time Polymerase Chain Reaction; Vidarabine | 2015 |
Haploidentical Bone Marrow Transplantation With Clofarabine and Busulfan Conditioning for a Child With Multiple Recurrent Acute Lymphoblastic Leukemia.
Topics: Adenine Nucleotides; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Arabinonucleosides; Bone Marrow Transplantation; Busulfan; Child, Preschool; Clofarabine; Humans; Male; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning; Transplantation, Homologous | 2016 |
Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Chromatin Assembly and Disassembly; Clofarabine; Depsipeptides; DNA Damage; Drug Synergism; Histone Code; Humans; Metabolic Networks and Pathways; Tumor Cells, Cultured; Vidarabine | 2016 |
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2016 |
HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy.
Topics: Adenine Nucleotides; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Follow-Up Studies; Haploidy; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia; Male; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Treatment Outcome | 2017 |
Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Busulfan; Chromatography, Liquid; Clofarabine; Drug Monitoring; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Isotopes; Limit of Detection; Tandem Mass Spectrometry; Transplantation Conditioning; Vidarabine | 2017 |
Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Busulfan; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Remission Induction; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Tumor Burden; Vidarabine | 2018 |
Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen.
Topics: Busulfan; Child; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine | 2022 |
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Topics: Adult; Aged; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myeloablative Agonists; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation, Homologous; Young Adult | 2023 |